haleon plc glp-1 receptor agonist medications Emerging Frontiers in Therapeutics: A Comprehensive Evidence Base (2025) New GLP-1 Pill Foundayo (Orforglipron)
Description
GLP-1 Receptor Agonist Market Share Companies such as Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi dominate this market due to their strong research capabilities, innovative drug formulations, and commitment to addressing diabetes and obesity challenges
GLP-1 is released in response to food intake
Manage gastrointestinal side effects, such as nausea or constipation, to ensure adherence and comfort
Market Drivers: Rising prevalence of diabetes and obesity is a key driver of revenue growth in the GLP-1 Receptor Agonist market
GLP-1 RAs reduced the composite outcome of all-cause mortality and HF hospitalization by 27% (HR 0.73
doi: 10.1186/s12933-015-0177-4 68 ZhangYZhouHWuWShiCHuSYinTet al
